Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical-stage programs in GI disorders and dyslipidemia. The Company discovers, develops and commercializes a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.